<DOC>
	<DOCNO>NCT00109928</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , etoposide , gemcitabine , methylprednisolone , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . PURPOSE : This phase II trial study well combination chemotherapy work treat patient newly diagnose stage II , stage III , stage IV T-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>S0350 Combination Chemotherapy Treating Patients With Newly Diagnosed Stage II , Stage III , Stage IV Peripheral T-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 2-year overall survival patient newly diagnose , bulky stage II stage III IV peripheral T-cell non-Hodgkin 's lymphoma treat cisplatin , etoposide , gemcitabine , methylprednisolone . Secondary - Determine toxicity regimen patient . - Determine response rate ( complete unconfirmed response , complete response , partial response ) patient treat regimen . - Determine progression-free survival patient treat regimen . OUTLINE : This pilot , multicenter study . Patients receive cisplatin IV 30-60 minute , etoposide IV 30-60 minute , methylprednisolone IV 5 minute day 1-4 . Patients also receive gemcitabine IV 30-60 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3-6 week , 3 month , every 6 month 3 year . PROJECTED ACCRUAL : A total 55 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis peripheral Tcell nonHodgkin 's lymphoma Newly diagnose , relapse progress disease 1 prior treatment nonplatinum base chemotherapy ( e.g. , CHOP ) Bulky stage II stage III IV disease The following histology eligible : Tcell prolymphocytic leukemia Tcell large granular lymphocytic leukemia Any NKcell leukemia Adult Tcell leukemia/lymphoma Mycosis fungoides/Sézary syndrome Lymphomatoid papulosis Nasaltype extranodal NK/Tcell lymphoma Enteropathytype Tcell lymphoma Hepatosplenic Tcell lymphoma Subcutaneous panniculitislike Tcell lymphoma Angioimmunoblastic Tcell lymphoma Primary cutaneous anaplastic large cell lymphoma ( ALCL ) ALCL CD30 , ALK , EMA expression ALCL morphology fail express ALK EMA allow provide Tcell lineage confirm immunotyping genetic test Bidimensionally measurable disease Adequate sample ( e.g. , core biopsy , especially multiple core biopsy ) original diagnostic specimen available Needle aspiration cytology consider adequate sample No clinical evidence Central nervous system ( CNS ) involvement lymphoma PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 2 time upper limit normal Renal Creatinine clearance ≥ 30 mL/min Cardiovascular No history congestive heart failure No history myocardial infarction No history unstable angina No history asymptomatic arrhythmia Ejection fraction normal multigated acquisition ( MUGA ) scan ( patient questionable cardiac history ) No history impair cardiac status Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity Mild clinical hearing loss allow provided patient willing accept potential worsen hearing loss No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix Must chest xray CT scan chest CT scan abdomen pelvis within past 28 day PRIOR CONCURRENT THERAPY : Biologic therapy At least 3 week since prior biologic therapy No concurrent routine use bone marrow colonystimulating factor Chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy cancer No concurrent radiotherapy Surgery Not specify Other No prior cytotoxic therapy cancer Concurrent enrollment SWOG8819 SWOG8947 allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
</DOC>